Polyrizon Advances PL-14 Nasal Spray with FDA Meeting

Polyrizon Ltd. ( (PLRZ) ) just unveiled an announcement.

Polyrizon Ltd. announced on December 8, 2025, that it successfully completed a pre-submission meeting with the U.S. FDA for its PL-14 Allergy Blocker Nasal Spray. This meeting is a significant milestone, providing early regulatory alignment and clarity on key requirements, which will help advance the PL-14 program efficiently. The global allergen blocker market is projected to grow significantly, driven by the rising incidence of allergies and demand for relief products. Polyrizon’s engagement with the FDA is expected to strengthen its development strategy and align its program with FDA expectations, potentially enhancing its industry positioning.

More about Polyrizon Ltd.

Polyrizon Ltd. is a biotechnology company specializing in the development of innovative intranasal products, particularly focusing on medical device hydrogels delivered as nasal sprays. These products form a protective barrier in the nasal cavity against viruses and allergens. The company is also working on bioadhesion and prolonged retention technologies for intranasal drug delivery.

Average Trading Volume: 3,156,807

Technical Sentiment Signal: Sell

Current Market Cap: $13.08M

For detailed information about PLRZ stock, go to TipRanks’ Stock Analysis page.